• Thurs news: Lilly’s weight-loss drug prevents diabetes. Merck pays $588M for bispecific. Amgen speaks out about bone density issues with obesity drug. PTC gets gene therapy approval. JNJ’s 340B legal fight. See more on our front page

Karyopharm - oncology





























Great. All the share value he destroyed over the last six months has almost been recovered. Almost.

Probably had little to do with the decline and less to do with the increase. The drug is getting some traction, which is good news. My hope is that the culture settles and becomes a decent place to work again. I'm still hesitant to buy into SC as a commercial leader. Seems very green.
 




Probably had little to do with the decline and less to do with the increase. The drug is getting some traction, which is good news. My hope is that the culture settles and becomes a decent place to work again. I'm still hesitant to buy into SC as a commercial leader. Seems very green.

A decent place to work under Ricky? I’m going to need a minute to wipe up the coffee I just spit out all over my keyboard.
 
































Where to begin? The current CEO is completely unprepared for their role and stopped maturing emotionally in junior high school, the product is at best an also-ran, roughly half of the staff are actively looking for other jobs...

Thank you for responding. You have a pipeline. Any good? Also, is the culture good? Fun?

Docs don’t use the drug?
 




Thank you for responding. You have a pipeline. Any good? Also, is the culture good? Fun?

Docs don’t use the drug?

The drug is getting some traction but it’s a huge slog. The culture under the current so-called leadership is on a downward trajectory. As far as future product potential, that’s no more than 50-50. The stock has nosedived in recent months, but if you look at the short activity you’ll see there’s a ton of people who think it has a lot further to fall. Hope that helps.

https://www.marketbeat.com/stocks/NASDAQ/KPTI/short-interest/